Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
24 hedge funds and large institutions have $26.7M invested in Agile Therapeutics in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $28M → $26.7M (-$1.33M)
8% less funds holding
Funds holding: 26 → 24 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.37M |
| 2 |
Renaissance Technologies
New York
|
+$168K |
| 3 |
JP Morgan Chase
New York
|
+$101K |
| 4 |
BlackRock
New York
|
+$50.3K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$44.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$112K |
| 2 |
NIM
Needham Investment Management
New York
|
-$89.4K |
| 3 |
VF
Virtu Financial
New York
|
-$88K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.58K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$2.79K |
AGRX Hedge Fund Activity: Q2 2019 in Review
24 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2019, worth a combined $26.7M — down 4.8% from $28M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AGRX and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $1.37M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $112K sold.
- 24 institutional investors held Agile Therapeutics (AGRX) as of Q2 2019, down from 26 in Q1 2019.
- Funds reported $26.7M of Agile Therapeutics stock for Q2 2019, down 4.8% quarter-over-quarter.
- 1 fund opened new Agile Therapeutics positions in Q2 2019 and 3 closed out, a net change of -2 holders.
- The largest Agile Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $1.37M added.
- The largest Agile Therapeutics seller in Q2 2019 was Pura Vida Investments, an estimated $112K sold.
Based on aggregated 13F filings for Q2 2019.